HEALTH.2011.2.2.2-1
HEALTH.2011.2.2.2-1
5 projects · €29,721,091 total EU contribution (project-level) · 68 participating organizations · 18 countries with participants
Total EU funding
Sum of EC max contribution fields for distinct projects in this topic.
€29,721,091
Countries active
Participant organizations by country (headquarters in CORDIS).
- CH (13)
- UK (11)
- Germany (6)
- France (6)
- IE (6)
- Italy (5)
- Spain (4)
- BE (3)
- Netherlands (3)
- CZ (2)
- IL (2)
- AT (1)
- EL (1)
- HU (1)
- LU (1)
- PT (1)
- SE (1)
- US (1)
Open calls
From the EU Funding & Tenders Portal, linked to this topic code when it matches the call identifier. Sync via yarn etl:funding.
No open or forthcoming calls linked to this topic in the database yet.
Top organizations
By number of distinct projects in this topic.
- CENTRE HOSPITALIER UNIVERSITAIRE DE TOULOUSE2 projects · FR
- STICHTING RADBOUD UNIVERSITEIT2 projects · NL
- UULM2 projects · DE
- UCC2 projects · IE
- ABGI FRANCE1 projects · FR
- Leiden University Medical Center1 projects · NL
- ADDS1 projects · CZ
- AE1 projects · LU
- ARCHER1 projects · US
- ARISTOTLE UNIVERSITY OF THESSALONIKI1 projects · EL
- Beacon Tech (BTL)1 projects · IL
- SJH1 projects · IE
Projects
Page 1 of 1
| Project | Programme | EU contribution | Total cost | |
|---|---|---|---|---|
A RANDOMIZED CLINICAL TRIAL TO EVALUATE THE EFFECTIVENESS OF A MULTI-MODAL INTERVENTION IN OLDER PEOPLE WITH TYPE 2 DIABETES ON FRAILTY AND QUALITY OF LIFE: THE MID-FRAIL STUDY MID-FRAIL-STUDY · 278803 | FP7 | €5,975,821 | €7,533,729 | Details |
VitaminD3-Omega3-Home Exercise- HeALTHy Ageing and Longevity Trial DO-HEALTH · 278588 | FP7 | €5,999,548 | €13,067,968 | Details |
Multi-modal effects of thyroid hormone replacement for untreated older adults with subclinical hypothyroidism; a randomised placebo-controlled trial TRUST · 278148 | FP7 | €5,963,787 | €7,764,598 | Details |
Virtual reality-Treadmill combined Intervention for enhancing Mobility and reducing falls in the Elderly V-TIME · 278169 | FP7 | €5,781,957 | €7,477,391 | Details |
A European multicentre double-blind placebo-controlled phase III trial of nilvadIpine in mild to moderate Alzheimer’s disease NILVAD · 279093 | FP7 | €5,999,978 | €7,916,016 | Details |